FDA removes bioscan requirement for Zevalin

In a move expected to make the radioimmunotherapy treatment Zevalin® much easier and more accessible to patients with indolent non-Hodgkin's lymphoma subtypes such as follicular lymphoma, the FDA has removed the need for a bioscan.

Previously, Zevalin treatment went as such:

  • Day 1: Patients were given an infusion of rituximab, then a diagnostic dose of radiolabeled Indium-111 Zevalin and a full-body scan at a nuclear imaging center within ten minutes.
  • Day 3 or 4: Patients repeat day 1.
  • Day 7, 8, or 9: Patients were given another infusion of rituximab and a 10-minute injection of the therapeutic dose of Zevalin.

The new FDA indication removes the scan requirement, meaning that patients will still be given two rituximab infusions as well as the 10-minute injection of Zevalin.

This newer, much simpler regimen, which makes the therapy much more accessible to patients and much easier to administer for doctors, will be known as "RRZ", or Rituximab, Rituximab, Zevalin.

Zevalin is owned by Spectrum Pharmaceuticals, which intends to unveil a new campaign in December at the American Society of Hematology meeting to promote Zevalin and RRZ.

Source: BusinessWire Press Release

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap